BR112018071097A2 - compostos heterocíclicos como inibidores de ret cinase - Google Patents

compostos heterocíclicos como inibidores de ret cinase

Info

Publication number
BR112018071097A2
BR112018071097A2 BR112018071097A BR112018071097A BR112018071097A2 BR 112018071097 A2 BR112018071097 A2 BR 112018071097A2 BR 112018071097 A BR112018071097 A BR 112018071097A BR 112018071097 A BR112018071097 A BR 112018071097A BR 112018071097 A2 BR112018071097 A2 BR 112018071097A2
Authority
BR
Brazil
Prior art keywords
retinase
inhibitors
heterocyclic compounds
compounds
relates
Prior art date
Application number
BR112018071097A
Other languages
English (en)
Other versions
BR112018071097B1 (pt
Inventor
Jordan Allan
Waszkowycz Bohdan
Alexander Fraser Fordyce Euan
Hynd George
Mark Sutton Jonathan
Newton Rebecca
Paoletta Silvia
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Priority to BR122023026297-2A priority Critical patent/BR122023026297A2/pt
Publication of BR112018071097A2 publication Critical patent/BR112018071097A2/pt
Publication of BR112018071097B1 publication Critical patent/BR112018071097B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a compostos da fórmula i que funcionam como inibidores da atividade enzimática de ret (rearranjada durante a transfecção) cinase: fórmula i em que het, ligações a, b, c e d, x1, x2, x3, x4, r2 e r3 são cada um como definidos aqui. a presente invenção se relaciona também com processos para a preparação destes compostos, com composições farmacêuticas compreendendo os mesmos e com seu uso no tratamento de disfunções proliferativas, tais como câncer, bem como outras doenças ou condições nas quais a atividade de ret cinase está implicada.
BR112018071097-0A 2016-04-15 2017-04-18 Composto heterocíclico como inibidor de ret cinase, composição farmacêutica e seu uso BR112018071097B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023026297-2A BR122023026297A2 (pt) 2016-04-15 2017-04-18 Composto heterocíclico como inibidor de ret cinase, composição farmacêutica e seu uso

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201606631 2016-04-15
GB1606631.8 2016-04-15
GB1619277.5 2016-11-14
GB201619277 2016-11-14
PCT/GB2017/051076 WO2017178844A1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as ret kinase inhibitors

Publications (2)

Publication Number Publication Date
BR112018071097A2 true BR112018071097A2 (pt) 2019-01-29
BR112018071097B1 BR112018071097B1 (pt) 2024-02-20

Family

ID=58633035

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122023026297-2A BR122023026297A2 (pt) 2016-04-15 2017-04-18 Composto heterocíclico como inibidor de ret cinase, composição farmacêutica e seu uso
BR112018071097-0A BR112018071097B1 (pt) 2016-04-15 2017-04-18 Composto heterocíclico como inibidor de ret cinase, composição farmacêutica e seu uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122023026297-2A BR122023026297A2 (pt) 2016-04-15 2017-04-18 Composto heterocíclico como inibidor de ret cinase, composição farmacêutica e seu uso

Country Status (23)

Country Link
US (3) US10954241B2 (pt)
EP (2) EP3960180A1 (pt)
JP (3) JP6943876B2 (pt)
KR (2) KR20220054894A (pt)
CN (2) CN109195972B (pt)
AU (3) AU2017250448C1 (pt)
BR (2) BR122023026297A2 (pt)
CA (1) CA3020778A1 (pt)
CY (1) CY1124478T1 (pt)
DK (1) DK3442980T3 (pt)
ES (1) ES2886587T3 (pt)
HR (1) HRP20211362T1 (pt)
HU (1) HUE056135T2 (pt)
IL (3) IL289793B2 (pt)
LT (1) LT3442980T (pt)
MX (2) MX2018012609A (pt)
PL (1) PL3442980T3 (pt)
PT (1) PT3442980T (pt)
RS (1) RS62322B1 (pt)
RU (1) RU2742115C2 (pt)
SG (2) SG10201911665UA (pt)
SI (1) SI3442980T1 (pt)
WO (1) WO2017178844A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506591TA (en) 2010-05-20 2015-09-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
KR20220054894A (ko) 2016-04-15 2022-05-03 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
PL3442535T3 (pl) 2016-04-15 2022-10-24 Cancer Research Technology Limited Związki heterocykliczne jako inhibitory kinazy ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
JP7328987B6 (ja) * 2018-04-05 2023-10-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｉ型ｉｒａｋ阻害剤としてのヘテロアリール化合物及びその使用
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
PL3860998T3 (pl) 2018-10-05 2024-06-17 Annapurna Bio Inc. Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj
BR112021019643A2 (pt) * 2019-04-03 2021-12-07 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
JP7461605B2 (ja) * 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2022140326A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds
TW202241419A (zh) * 2020-12-22 2022-11-01 美商基利科學股份有限公司 ６－取代之吲哚化合物
CA3214808A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
WO2023064843A1 (en) 2021-10-15 2023-04-20 Stemline Therapeutics, Inc. Inhibitors of mutant ret kinases for use in treating cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE60004781T2 (de) * 1999-01-11 2004-07-08 Princeton University Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
BRPI0618622A2 (pt) * 2005-11-17 2011-09-06 Osi Pharm Inc composto, composição, e, uso de um composto
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
CA2635231C (en) 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
SI2526933T1 (sl) 2006-09-22 2015-07-31 Pharmacyclics, Inc. Inhibitorji Bruton tirozin kinaze
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MY191407A (en) 2008-01-04 2022-06-27 Intellikine Llc Certain chemical entities, compositions and methods
US9096611B2 (en) * 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
ES2651682T3 (es) 2009-11-05 2018-01-29 Rhizen Pharmaceuticals S.A. Moduladores de cinasa novedosos
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
JP6047149B2 (ja) 2011-05-04 2016-12-21 インテリカイン， エルエルシー 併用の医薬組成物およびその使用
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
CA2846496C (en) * 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
EP2776441A4 (en) 2011-11-08 2015-04-08 Intellikine Llc TREATMENT METHOD WITH MULTIPLE PHARMACEUTICAL AGENTS
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
EP3057970A1 (en) 2013-10-18 2016-08-24 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
GB201321146D0 (en) * 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10307425B2 (en) 2015-01-26 2019-06-04 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
KR20220054894A (ko) * 2016-04-15 2022-05-03 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
PL3442535T3 (pl) * 2016-04-15 2022-10-24 Cancer Research Technology Limited Związki heterocykliczne jako inhibitory kinazy ret

Also Published As

Publication number Publication date
KR20180134983A (ko) 2018-12-19
DK3442980T3 (da) 2021-08-30
US10954241B2 (en) 2021-03-23
HUE056135T2 (hu) 2022-01-28
BR122023026297A2 (pt) 2024-01-16
EP3442980B1 (en) 2021-06-09
CN109195972A (zh) 2019-01-11
RU2018138471A3 (pt) 2020-05-15
HRP20211362T1 (hr) 2021-11-26
US20210155628A1 (en) 2021-05-27
PT3442980T (pt) 2021-09-13
LT3442980T (lt) 2021-09-27
AU2017250448A1 (en) 2018-11-01
EP3960180A1 (en) 2022-03-02
IL262185B (en) 2022-02-01
CA3020778A1 (en) 2017-10-19
EP3442980A1 (en) 2019-02-20
IL289793A (en) 2022-03-01
SG11201808878UA (en) 2018-11-29
JP2019515903A (ja) 2019-06-13
WO2017178844A1 (en) 2017-10-19
AU2020220079A1 (en) 2020-09-03
US11548896B2 (en) 2023-01-10
IL262185A (en) 2018-11-29
IL297192A (en) 2022-12-01
AU2017250448B2 (en) 2020-05-21
RU2018138471A (ru) 2020-05-15
JP2021193108A (ja) 2021-12-23
AU2017250448C1 (en) 2021-01-07
CN109195972B (zh) 2022-10-28
MX2018012609A (es) 2019-08-01
MX2021013110A (es) 2021-11-17
US20190106425A1 (en) 2019-04-11
IL289793B2 (en) 2023-03-01
JP2023159230A (ja) 2023-10-31
RU2742115C2 (ru) 2021-02-02
SG10201911665UA (en) 2020-01-30
PL3442980T3 (pl) 2021-12-06
ES2886587T3 (es) 2021-12-20
KR20220054894A (ko) 2022-05-03
IL289793B (en) 2022-11-01
AU2020220079B2 (en) 2022-04-21
SI3442980T1 (sl) 2021-11-30
CY1124478T1 (el) 2022-07-22
AU2022203916A1 (en) 2022-06-23
RS62322B1 (sr) 2021-10-29
JP6943876B2 (ja) 2021-10-06
CN115650985A (zh) 2023-01-31
KR102390578B1 (ko) 2022-04-26
BR112018071097B1 (pt) 2024-02-20
US20230339954A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
BR112018071097A2 (pt) compostos heterocíclicos como inibidores de ret cinase
BR112017012402A2 (pt) derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112015014701B8 (pt) Derivados de benzimidazol e seus usos
BR112022010561A2 (pt) Compostos poli-heterocíclicos como inibidores de mettl3
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112015022462A2 (pt) inibidores de ido
BR112015024671A2 (pt) derivados de ureia úteis como inibidores de quinase
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
BR112014022000A2 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015021701A2 (pt) novos compostos inibidores da fosfoestearase tipo 10a

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023026297-2 PROTOCOLO 870230110160 EM 13/12/2023 17:30.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/04/2017, OBSERVADAS AS CONDICOES LEGAIS